S3maglutide

Description

What Is S3maglutide?

S3maglutide is a long‑acting synthetic analog of human glucagon‑like pep‑1 (GLP‑1), developed as a once‑weekly injectable or daily oral therapy. It belongs to the incretin mimetic class of drugs, designed to enhance glucose‑dependent insulin secretion and improve metabolic outcomes. Semaglutide has been approved for type 2 diabetes management and obesity treatment, with growing interest in its cardiometabolic protective effects.

Mechanism of Action

S3maglutide binds to GLP‑1 receptors in pancreatic β‑cells, stimulating insulin release in a glucose‑dependent manner. It suppresses glucagon secretion from α‑cells, reducing hepatic glucose output. Additionally, it slows gastric emptying, prolonging satiety and reducing caloric intake. These combined effects lead to improved glycemic control and significant weight reduction. Beyond metabolic regulation, GLP‑1 receptor activation contributes to cardiovascular and renal protection, lowering risks of major adverse cardiac events and diabetic kidney disease progression.

Research & Clinical Data

Clinical trials (SUSTAIN, STEP programs) demonstrate S3maglutide’s efficacy in lowering HbA1c, reducing body weight by 10–15%, and improving cardiovascular outcomes. It is available as Ozempic (weekly injection for diabetes), Rybelsus (oral tablet for diabetes), and Wegovy (weekly injection for obesity). Side effects include gastrointestinal symptoms (nausea, vomiting, diarrhea), with rare risks of pancreatitis and worsening diabetic retinopathy. Contraindications include personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Purity & Quality

Pharmaceutical‑grade p3ptide. Certificate of Analysis available per batch. Regulatory status: FDA‑ and EMA‑approved for diabetes and obesity.

Classification & Handling Class: GLP‑1 receptor agonist | Source: Synthetic p3ptide analog | Administration: Subcutaneous injection or oral tablet | Storage: 2–8°C refrigerated, protect from light | Regulatory: FDA/EMA approved